TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31079189

Group type: COMPARATOR
Intervention: Immediate combination therapy (tamsulosin-dutasteride)
Number of subjects: 10238

Group type: EXPERIMENTAL
Intervention: Delayed combination therapy (switching from tamsulosin monotherapy after 6 months)
Number of subjects: 10238

Group type: EXPERIMENTAL
Intervention: Delayed combination therapy (switching from tamsulosin monotherapy after 12 months)
Number of subjects: 10238

Group type: EXPERIMENTAL
Intervention: Delayed combination therapy (switching from tamsulosin monotherapy after 24 months)
Number of subjects: 10238
Study: 30428445

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for panic disorder with agoraphobia (PD/AG)
Number of subjects: 42
Study: 28842165

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (Stages 1-3)
Number of subjects: 12174
Study: 26494524

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone-naloxone (OXN PR) 5 mg oxycodone and 25 mg naloxone, twice daily for 16 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone-naloxone (OXN PR)
Number of subjects: 202
Study: 24364618

Group type: EXPERIMENTAL
Intervention: Nicotine (0.6 mg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (male: 0.3g/kg; female: 0.27g/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nicotine (0.6 mg) and Low-dose alcohol (male: 0.3g/kg; female: 0.27g/kg)
Number of subjects: 87
Study: 21109748

Group type: EXPERIMENTAL
Intervention: Specific IgG4 testing against foods
Number of subjects: 73

Group type: COMPARATOR
Intervention: Double-blind placebo-controlled food challenge
Number of subjects: 73
Study: 19737321

Group type: EXPERIMENTAL
Intervention: Thermal therapy with far-infrared rays at 40 degrees C for 15 minutes once a day on two days a week for a total of 18 sessions
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group received a plain adhesive patch placed on the same acupoint
Number of subjects: 41
Study: 16670409

Group type: EXPERIMENTAL
Intervention: Naltrexone plus medical management (100 mg/d)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: CBI plus medical management and placebos
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Both naltrexone and CBI plus medical management
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: CBI without pills or medical management
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Placebo plus medical management
Number of subjects: 1383
Study: 15543092

Group type: EXPERIMENTAL
Intervention: PSA testing as a serum tumor marker for early detection and monitoring of treatment response.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxane-based regimens in phase 3 randomized controlled trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agents such as selenium and vitamin E in chemoprevention trials.
Number of subjects: 0
Study: 11500333

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation program (SI)
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Sustained quitters
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Smokers with LRI
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Smokers averaging one LRI/yr over 5 years
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Smokers with more than one LRI/yr
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Chronic bronchitis
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Smoking and LRI interaction
Number of subjects: 5887
Study: 9640015

Group type: EXPERIMENTAL
Intervention: Pattern stimulation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flash stimulation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arteriosclerosis optic nerve atrophy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Toxic neuropathy optic nerve atrophy
Number of subjects: 48
Study: 7943490

Group type: EXPERIMENTAL
Intervention: Personal invitation letter with appointment time
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Personal invitation letter without appointment time
Number of subjects: 2266

Group type: EXPERIMENTAL
Intervention: Second letter to nonattenders
Number of subjects: 2266

Group type: COMPARATOR
Intervention: Distance from the program
Number of subjects: 2266

Group type: COMPARATOR
Intervention: Percentage of non-English speaking women in a neighborhood
Number of subjects: 2266

Group type: COMPARATOR
Intervention: Socioeconomic status of areas
Number of subjects: 2266
Study: 3128320

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Granuflex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paraffin gauze dressing (Jelonet)
Number of subjects: 0
Study: 30550208

Group type: EXPERIMENTAL
Intervention: Avoiding allergic plant foods intake (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No avoidance of allergic plant foods (Group B)
Number of subjects: 40
Study: 28444964

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25658223

Group type: EXPERIMENTAL
Intervention: Active promotional strategies (face-to-face offers and telephone calls)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive promotional strategies (letters and bag stuffers)
Number of subjects: 30
Study: 23553478

Group type: EXPERIMENTAL
Intervention: Carbidopa (average daily dose of 480 mg, range 325-600 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbidopa
Number of subjects: 12
Study: 21180676

Group type: EXPERIMENTAL
Intervention: Milk supplemented with Lactobacillus rhamnosus LB21 (107 CFU/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard control milk (placebo)
Number of subjects: 18
Study: 18202961

Group type: EXPERIMENTAL
Intervention: EP + A (n = 31): CEE 0.625 mg plus MPA 2.5 mg and methyltestosterone 2.0 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: EP (n = 29): CEE 0.625 mg plus MPA 2.5 mg and placebo
Number of subjects: 60
Study: 16395548

Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid (ASA)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Healthy control group (no medication)
Number of subjects: 317
Study: 12728160

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (medical management)
Number of subjects: 55
Study: 10810433

Group type: EXPERIMENTAL
Intervention: Medroxyprogesteroneacetate (MPA)
Number of subjects: 163

Group type: COMPARATOR
Intervention: CAF adjuvant chemotherapy
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Bcl-2 and p53 expression
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: MIB-1
Number of subjects: 163
Study: 9238878

Group type: EXPERIMENTAL
Intervention: Dental rinse containing 2.18% aluminum lactate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Vehicle control dental rinse
Number of subjects: 56
Study: 1459529

Group type: EXPERIMENTAL
Intervention: BCAA (0.24g per kg body weight)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Casein (equinitrogenous amount)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 49

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 49
Study: 6506819

Group type: EXPERIMENTAL
Intervention: Interval run exercise therapy for untreated patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Interval run exercise therapy for propranolol-treated patients
Number of subjects: 2
Study: 30126775

Group type: EXPERIMENTAL
Intervention: Cementless bone preserving stem (Fitmore)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cementless straight stem (CLS Spotorno)
Number of subjects: 140
Study: 29587159

Group type: EXPERIMENTAL
Intervention: MEmory Specificity Training (MEST)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Psychoeducation and Supportive Counselling (PSC)
Number of subjects: 62
Study: 26278704

Group type: EXPERIMENTAL
Intervention: Automated group (Group 1) using target-controlled infusion system (Veryark‐CLMRIS‐I‐China)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group 2) using routinely used acceleromyography device (TOF Watch SX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 0
Study: 22397516

Group type: EXPERIMENTAL
Intervention: Deep peeling using phenol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Percutaneous collagen induction combined with TCA 20%
Number of subjects: 24
Study: 22240619

Group type: EXPERIMENTAL
Intervention: AnaConDa
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 20187281

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control training (CON)
Number of subjects: 18
Study: 17937851

Group type: EXPERIMENTAL
Intervention: Forlax (20 g/d)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Lactulose (15 mL/d)
Number of subjects: 216
Study: 14693984

Group type: EXPERIMENTAL
Intervention: Active Anodyne Therapy System (ATS) treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 27
Study: 12511184

Group type: COMPARATOR
Intervention: Diabetes Type 2
Number of subjects: 52

Group type: COMPARATOR
Intervention: Diabetes Type 1
Number of subjects: 52

Group type: COMPARATOR
Intervention: Both types of DM
Number of subjects: 52
Study: 9689294

Group type: EXPERIMENTAL
Intervention: Protective creams (3 different creams)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Protective creams (1 product)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Petrolatum (control)
Number of subjects: 15
Study: 7858795

Group type: EXPERIMENTAL
Intervention: Foam splints
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Eggshell foam
Number of subjects: 41

Group type: COMPARATOR
Intervention: Duoderm
Number of subjects: 41

Group type: COMPARATOR
Intervention: Heel protector boots
Number of subjects: 41
Study: 2570700

Group type: EXPERIMENTAL
Intervention: 200 mg diprafenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 mg propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29579327

Group type: EXPERIMENTAL
Intervention: Trends in carcinoembryonic antigen (CEA) measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single CEA measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trends in CEA measurements
Number of subjects: 0
Study: 28213365

Group type: EXPERIMENTAL
Intervention: TAS-102 35 mg/m2 orally twice daily after meals on days 1 through 5 and 8 through 12 of each 28‐day cycle (n = 534)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Matching placebo (n = 266)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: TAS-102
Number of subjects: 800
Study: 26453484

Group type: EXPERIMENTAL
Intervention: High-motivating positive affect (interest)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low-motivating positive affect (serenity)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: High-motivating negative affect (disgust)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Low-motivating negative affect (anxiety)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Neutral state
Number of subjects: 155
Study: 23196118

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-Nissen fundoplication
Number of subjects: 20
Study: 21672344

Group type: EXPERIMENTAL
Intervention: Topiramate (n = 46)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 86
Study: 19485581

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 57
Study: 17267379

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 51
Study: 12897995

Group type: EXPERIMENTAL
Intervention: Continuous morphine (10 micro g/kg per hour)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intermittent morphine (30 micro g/kg per 3 hours)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Continuous morphine and Intermittent morphine
Number of subjects: 68
Study: 10736078

Group type: EXPERIMENTAL
Intervention: Desflurane 6% end-tidal
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fentanyl 10 microg.kg‐1 bolus i.v. with an infusion of 3 microg.kg‐1.h‐1
Number of subjects: 47
Study: 8932966

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy with eye movement
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy without eye movement (eyes-fixed)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Imaginal flooding (previous study for comparison)
Number of subjects: 17
Study: 1416894

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 400 mg orally per day for 10 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally per day for 10 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3927068

Group type: EXPERIMENTAL
Intervention: Ventilation group (10 breaths/min with 100% oxygen at a tidal volume of 10 ml/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonventilation group (apneic oxygenation at zero end-expiratory pressure)
Number of subjects: 20
Study: 28575321

Group type: EXPERIMENTAL
Intervention: PANSS-6
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: PANSS-30
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: PANSS-6 and PANSS-30
Number of subjects: 577
Study: 26909888

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60 min, 2 times/week for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 61
Study: 22389940

Group type: EXPERIMENTAL
Intervention: Sensory-enhanced hatha yoga (3 weeks, ≥9 sessions)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no yoga)
Number of subjects: 70
Study: 20688033

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Both DES and BMS
Number of subjects: 626
Study: 17506001

Group type: EXPERIMENTAL
Intervention: Imipenem 0.5 g x 3 for 5-7 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 73
Study: 15682068

Group type: EXPERIMENTAL
Intervention: Bone Marrow (BM) Transplantation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Peripheral Blood Stem Cell (PBSC) Transplantation
Number of subjects: 72
Study: 12131234

Group type: EXPERIMENTAL
Intervention: Activities of daily living intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial activity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of activities of daily living and psychosocial activity intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 0
Study: 11721446

Group type: EXPERIMENTAL
Intervention: Haloperidol plus Ginkgo biloba (EGb)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Haloperidol plus placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 54
Study: 7595267

Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2301243

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7436639

Group type: EXPERIMENTAL
Intervention: Patient-operated hypertension group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nurse-operated hypertension clinic (control)
Number of subjects: 52
Study: 31845141

Group type: EXPERIMENTAL
Intervention: Laparoscopic-completed approach
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach (intention-to-treat)
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: Laparoscopic Hartmann's procedure and primary anastomosis
Number of subjects: 3756

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 3756
Study: 30808847

Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (pre-dilution mode)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (post-dilution mode)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 22
Study: 28580579

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg FI
Number of subjects: 340

Group type: COMPARATOR
Intervention: Secukinumab 300 mg RAN
Number of subjects: 340
Study: 24909549

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m(2) on RT days 1, 22, and 43 (Arm A)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cisplatin (20 mg/m(2)/day) and 5-fluorouracil (5-FU; 1000 mg/m(2)/day) continuous 96-hour infusions on RT weeks 1 and 4 (Arm B)
Number of subjects: 69
Study: 23845018

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Paliperidone extended release (ER)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Paliperidone ER placebo
Number of subjects: 45
Study: 21514033

Group type: EXPERIMENTAL
Intervention: Patient Global Impression of Improvement (PGI-I)
Number of subjects: 299
Study: 18495387

Group type: EXPERIMENTAL
Intervention: Cumulus method for assessing mammographic density
Number of subjects: 177

Group type: COMPARATOR
Intervention: Standard mammogram form (SMF) for assessing mammographic density
Number of subjects: 177
Study: 17060764

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LGBP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LGBP) and Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 83
Study: 12735661

Group type: EXPERIMENTAL
Intervention: FP 125 microg b.i.d.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: FP 50 microg b.i.d.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 10652956

Group type: EXPERIMENTAL
Intervention: Sequential estrogen/progestin (beta estradiol/norethisterone acetate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous estrogen/progestin (beta estradiol/norethisterone acetate)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Estrogen alone (beta estradiol)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Estrogen/progestin-treated women
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Estrogen/progestin groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Women with > or = 50% drop in B‐ALP at 6 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Decrease in B‐ALP at 6 months
Number of subjects: 90
Study: 9330124

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spirapril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 1534042

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 4036269

Group type: EXPERIMENTAL
Intervention: Combined vaccine against measles, mumps, and rubella (two doses: first at 18 months, second at 12 years)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Urban areas
Number of subjects: 247

Group type: COMPARATOR
Intervention: Rural areas
Number of subjects: 247
Study: 29882281

Group type: EXPERIMENTAL
Intervention: UDS video training module
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard UDS teaching document
Number of subjects: 20
Study: 27311730

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg IV days 1 and 15) and Everolimus (10 mg PO daily)
Number of subjects: 17
Study: 24984192

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22160931

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study: 20231565

Group type: EXPERIMENTAL
Intervention: Salsalate 3.0 g/d
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/d
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Salsalate 4.0 g/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 18385624

Group type: EXPERIMENTAL
Intervention: Balance training (15 sessions using force platform biofeedback)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional stroke inpatient rehabilitation program
Number of subjects: 41
Study: 16284466

Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate gel
Number of subjects: 180

Group type: COMPARATOR
Intervention: K-Y Jelly
Number of subjects: 180
Study: 12882907

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 0
Study: 10450427

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (non-users of ITNs)
Number of subjects: 120
Study: 9231304

Group type: EXPERIMENTAL
Intervention: Clozapine (mean 324 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Typical neuroleptics (mean 465 mg chlorpromazine‐equivalents daily)
Number of subjects: 40
Study: 1806186

Group type: EXPERIMENTAL
Intervention: Anti-CD3 monoclonal antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-TNF monoclonal antibodies
Number of subjects: 0
Study: 6410547

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1) for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 40